Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 3/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 6/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | TOP1 | P11387 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107909 | 0.96 | TRPV3 (0.40) | CTSSTRPV3SCN9ATOP1 | |
| SCHEMBL1107875 | 0.93 | TRPV3 (0.41) | KIF11TRPV3SCN9A | |
| SCHEMBL1107937 | 0.93 | TRPV3 (0.43) | KIF11TRPV3SCN9A | |
| SCHEMBL1107931 | 0.92 | KIF11 (0.46) | PIM1PIM3PIM2KIF11TRPV3 | |
| SCHEMBL1107966 | 0.92 | CDK2 (0.39) | HSD17B1PIM1PIM3PIM2TRPV3 | |
| SCHEMBL1107942 | 0.89 | CTSS (0.52) | HSD17B1PIM1PIM3CTSS | |
| SCHEMBL1107944 | 0.88 | TRPV3 (0.40) | PIM1PIM3CTSSTRPV3SCN9A | |
| SCHEMBL1107929 | 0.86 | TRPV3 (0.39) | KIF11TRPV3SCN9ATOP1 | |
| SCHEMBL1107938 | 0.86 | CTSS (0.52) | PIM1PIM3CTSS | |
| SCHEMBL1107923 | 0.86 | CTSS (0.52) | PIM1PIM3CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153277-B2 | Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153277-B2 | Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | OXA1L, SLCO4C1, SLCO2B1 | HSD17B1 665/4885PIM1 1477/4885PIM3 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.